Id
|
Protein
|
PTM type
|
Site
|
Species
|
Disease
|
Celline
|
Drug
|
Regulatory
|
Score
|
Ref.
|
acc0051 |
cullin |
neddylation |
unclear |
human |
Glioblastoma |
U251 |
MLN4924 |
Unresolved |
4.0 |
25904638
|
acc0052 |
cullin |
neddylation |
unclear |
human |
Glioblastoma |
A172 |
MLN4924 |
Unresolved |
4.0 |
25904638
|
acc0053 |
NADPH |
oxidation |
unclear |
rat |
Breast Cancer |
|
Tamoxifen |
Negative |
4.5 |
4004771
|
acc0054 |
NADPH |
oxidation |
unclear |
rat |
Endometrial Cancer |
|
Tamoxifen |
Negative |
4.5 |
4004771
|
acc0055 |
VEGFR2 |
phosphorylation |
Tyr1059 |
mouse |
Osteosarcoma |
MC3T3-E1 |
Osimertinib |
Unresolved |
4.0 |
23444047
|
acc0056 |
VEGFR2 |
phosphorylation |
Tyr1059 |
mouse |
Osteosarcoma |
UMR-106 |
Osimertinib |
Unresolved |
4.0 |
23444047
|
acc0057 |
JNK |
phosphorylation |
Thr183 |
rat |
Insulinoma |
RINm5F |
Hypericin |
Unresolved |
4.0 |
26182357
|
acc0058 |
JNK |
phosphorylation |
Tyr185 |
rat |
Insulinoma |
RINm5F |
Hypericin |
Unresolved |
4.0 |
26182357
|
acc0059 |
ERK1 |
phosphorylation |
Thr202 |
rat |
Insulinoma |
RINm5F |
Hypericin |
Unresolved |
4.0 |
26182357
|
acc0060 |
ERK1 |
phosphorylation |
Tyr204 |
rat |
Insulinoma |
RINm5F |
Hypericin |
Unresolved |
4.0 |
26182357
|
acc0061 |
ERK2 |
phosphorylation |
Thr185 |
rat |
Insulinoma |
RINm5F |
Hypericin |
Unresolved |
4.0 |
26182357
|
acc0062 |
ERK2 |
phosphorylation |
Tyr187 |
rat |
Insulinoma |
RINm5F |
Hypericin |
Unresolved |
4.0 |
26182357
|
acc0063 |
eIF2alpha |
phosphorylation |
unclear |
human |
Glioblastoma |
GBM |
Luteolin |
Unresolved |
4.0 |
30798142
|
acc0064 |
PERK |
phosphorylation |
unclear |
human |
Glioblastoma |
GBM |
Luteolin |
Unresolved |
4.0 |
30798142
|
acc0065 |
CHOP |
phosphorylation |
unclear |
human |
Glioblastoma |
GBM |
Luteolin |
Unresolved |
4.0 |
30798142
|
acc0066 |
ATF4 |
phosphorylation |
unclear |
human |
Glioblastoma |
GBM |
Luteolin |
Unresolved |
4.0 |
30798142
|
acc0067 |
SMAD2 |
phosphorylation |
unclear |
human |
Glioma |
LN-308 |
ISTH1047 |
Unresolved |
4.0 |
31530630
|
acc0068 |
Smad2 |
phosphorylation |
unclear |
mouse |
Glioma |
SMA-560 |
ISTH1047 |
Unresolved |
4.0 |
31530630
|
acc0069 |
ERK1 |
phosphorylation |
Thr202 |
human |
Myeloma |
MM |
Z-VAD-FMK/PS-341 |
Unresolved |
4.0 |
14627979
|
acc0070 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Myeloma |
MM |
Z-VAD-FMK/PS-341 |
Unresolved |
4.0 |
14627979
|
acc0071 |
ERK2 |
phosphorylation |
Thr185 |
human |
Myeloma |
MM |
Z-VAD-FMK/PS-341 |
Unresolved |
4.0 |
14627979
|
acc0072 |
ERK2 |
phosphorylation |
Tyr187 |
human |
Myeloma |
MM |
Z-VAD-FMK/PS-341 |
Unresolved |
4.0 |
14627979
|
acc0073 |
STAT3 |
phosphorylation |
Tyr705 |
human |
Myeloma |
MM |
Z-VAD-FMK/PS-341 |
Unresolved |
4.0 |
14627979
|
acc0074 |
AKT |
phosphorylation |
Ser473 |
human |
Myeloma |
MM |
Z-VAD-FMK/PS-341 |
Unresolved |
4.0 |
14627979
|
acc0075 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Hepatocellular Carcinoma |
HuH-7-EGFRvIII |
CH12 + Sorafenib |
Unresolved |
4.0 |
22787432
|
acc0076 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Hepatocellular Carcinoma |
SMMC-7721 |
CH12 + Sorafenib |
Unresolved |
4.0 |
22787432
|
acc0077 |
AKT |
phosphorylation |
Thr308 |
human |
Hepatocellular Carcinoma |
HuH-7-EGFRvIII |
CH12 + Sorafenib |
Unresolved |
4.0 |
22787432
|
acc0078 |
AKT |
phosphorylation |
Thr308 |
human |
Hepatocellular Carcinoma |
SMMC-7721 |
CH12 + Sorafenib |
Unresolved |
4.0 |
22787432
|
acc0079 |
STAT3 |
phosphorylation |
Tyr705 |
human |
Hepatocellular Carcinoma |
HuH-7-EGFRvIII |
CH12 + Sorafenib |
Unresolved |
4.0 |
22787432
|
acc0080 |
STAT3 |
phosphorylation |
Tyr705 |
human |
Hepatocellular Carcinoma |
SMMC-7721 |
CH12 + Sorafenib |
Unresolved |
4.0 |
22787432
|
acc0081 |
MARCKS |
phosphorylation |
Ser152 |
human |
Myeloma |
RPMI8226-R5 |
Bortezomib |
Negative |
5.0 |
25179733
|
acc0082 |
MARCKS |
phosphorylation |
Ser152 |
human |
Myeloma |
MM.1R |
Bortezomib |
Negative |
5.0 |
25179733
|
acc0083 |
MARCKS |
phosphorylation |
Ser156 |
human |
Myeloma |
MM.1R |
Bortezomib |
Negative |
5.0 |
25179733
|
acc0084 |
MARCKS |
phosphorylation |
Ser156 |
human |
Myeloma |
RPMI8226-R5 |
Dexamethasone |
Negative |
5.0 |
25179733
|
acc0085 |
MARCKS |
phosphorylation |
Ser156 |
human |
Myeloma |
MM.1R |
Dexamethasone |
Negative |
5.0 |
25179733
|
acc0086 |
MARCKS |
phosphorylation |
Ser156 |
human |
Myeloma |
RPMI8226-R5 |
Doxorubicin |
Negative |
5.0 |
25179733
|
acc0087 |
MARCKS |
phosphorylation |
Ser156 |
human |
Myeloma |
MM.1R |
Doxorubicin |
Negative |
5.0 |
25179733
|
acc0088 |
MARCKS |
phosphorylation |
Ser156 |
human |
Myeloma |
RPMI8226-R5 |
Lenalidomide |
Negative |
5.0 |
25179733
|
acc0089 |
MARCKS |
phosphorylation |
Ser156 |
human |
Myeloma |
MM.1R |
Lenalidomide |
Negative |
5.0 |
25179733
|
acc0090 |
MARCKS |
phosphorylation |
Ser156 |
human |
Myeloma |
MM.1R |
MG132 |
Negative |
5.0 |
25179733
|
acc0091 |
MARCKS |
phosphorylation |
Ser152 |
human |
Myeloma |
RPMI8226-R5 |
Dexamethasone |
Negative |
5.0 |
25179733
|
acc0092 |
MARCKS |
phosphorylation |
Ser152 |
human |
Myeloma |
MM.1R |
Dexamethasone |
Negative |
5.0 |
25179733
|
acc0093 |
MARCKS |
phosphorylation |
Ser152 |
human |
Myeloma |
RPMI8226-R5 |
Doxorubicin |
Negative |
5.0 |
25179733
|
acc0094 |
MARCKS |
phosphorylation |
Ser152 |
human |
Myeloma |
MM.1R |
Doxorubicin |
Negative |
5.0 |
25179733
|
acc0095 |
MARCKS |
phosphorylation |
Ser152 |
human |
Myeloma |
RPMI8226-R5 |
Lenalidomide |
Negative |
5.0 |
25179733
|
acc0096 |
MARCKS |
phosphorylation |
Ser152 |
human |
Myeloma |
MM.1R |
Lenalidomide |
Negative |
5.0 |
25179733
|
acc0097 |
MARCKS |
phosphorylation |
Ser152 |
human |
Myeloma |
MM.1R |
MG132 |
Negative |
5.0 |
25179733
|
acc0098 |
MARCKS |
phosphorylation |
Ser156 |
human |
Myeloma |
RPMI8226-R5 |
Bortezomib |
Negative |
5.0 |
25179733
|
acc0099 |
EGFR |
phosphorylation |
Tyr1068 |
human |
Skin Cancer |
Colo16 |
AEE788 |
Unresolved |
4.0 |
15756022
|
acc0100 |
VEGFR2 |
phosphorylation |
Tyr1054 |
human |
Skin Cancer |
Colo16 |
AEE788 |
Unresolved |
4.0 |
15756022
|